Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda C Guidon

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
The Oncologist|November 29, 2018
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the LiteratureKerry L Reynolds, Amanda C Guidon
Muscle & Nerve|August 15, 2018
On the double: Early immunotherapy speeds recovery of ocular myasthenic weaknessAmanda C Guidon, Lisa D Hobson-Webb
The New England Journal of Medicine|October 24, 2019
Case 22-2019: A 65-Year-Old Woman with Myopathy. ReplyMason W Freeman, Amanda C Guidon, Sheila L Arvikar
Muscle & Nerve|December 14, 2020
Dual hereditary and immune-mediated neuromuscular diagnoses after cancer immunotherapyNadim S Jiwa, Donald P Lawrence, Amanda C Guidon
Muscle & Nerve|June 10, 2022
Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practiceJoome Suh, Virginia Clarke, Anthony A Amato, et al.
Muscle & Nerve|August 31, 2019
Rituximab desensitization in two patients with muscle-specific kinase myasthenia gravisJoome Suh, Benjamin R Slawski, Aidan A Long, et al.
The Oncologist|March 29, 2022
Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular SymptomsJohn Y Rhee, Nurhan Torun, Tomas G Neilan, et al.
Neuro-Oncology Advances|December 3, 2021
A review of neurotoxicities associated with immunotherapy and a framework for evaluationLeeann B Burton, Mahsa Eskian, Amanda C Guidon, et al.
The New England Journal of Medicine|April 18, 2019
Case 12-2019: A 60-Year-Old Man with Weakness and Difficulty ChewingChristopher T Doughty, Amanda C Guidon, Sabrina Paganoni, et al.
Muscle & Nerve|August 11, 2021
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years oldChristopher T Doughty, Joome Suh, William S David, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
The Oncologist|November 29, 2018
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the LiteratureKerry L Reynolds, Amanda C Guidon
Muscle & Nerve|August 15, 2018
On the double: Early immunotherapy speeds recovery of ocular myasthenic weaknessAmanda C Guidon, Lisa D Hobson-Webb
The New England Journal of Medicine|October 24, 2019
Case 22-2019: A 65-Year-Old Woman with Myopathy. ReplyMason W Freeman, Amanda C Guidon, Sheila L Arvikar
Muscle & Nerve|December 14, 2020
Dual hereditary and immune-mediated neuromuscular diagnoses after cancer immunotherapyNadim S Jiwa, Donald P Lawrence, Amanda C Guidon
Muscle & Nerve|June 10, 2022
Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practiceJoome Suh, Virginia Clarke, Anthony A Amato, et al.
Muscle & Nerve|August 31, 2019
Rituximab desensitization in two patients with muscle-specific kinase myasthenia gravisJoome Suh, Benjamin R Slawski, Aidan A Long, et al.
The Oncologist|March 29, 2022
Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular SymptomsJohn Y Rhee, Nurhan Torun, Tomas G Neilan, et al.
Neuro-Oncology Advances|December 3, 2021
A review of neurotoxicities associated with immunotherapy and a framework for evaluationLeeann B Burton, Mahsa Eskian, Amanda C Guidon, et al.
The New England Journal of Medicine|April 18, 2019
Case 12-2019: A 60-Year-Old Man with Weakness and Difficulty ChewingChristopher T Doughty, Amanda C Guidon, Sabrina Paganoni, et al.
Muscle & Nerve|August 11, 2021
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years oldChristopher T Doughty, Joome Suh, William S David, et al.
Pageof 5